-
1
-
-
78649686908
-
Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: A comparative review
-
Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab. 2011;13:7-18.
-
(2011)
Diabetes Obes Metab
, vol.13
, pp. 7-18
-
-
Deacon, C.F.1
-
2
-
-
77951168113
-
Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice
-
Sauvé M, Ban K, Momen MA, Zhou YQ, Henkelman RM, Husain M, Drucker DJ. Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. Diabetes. 2010;59:1063-1073.
-
(2010)
Diabetes
, vol.59
, pp. 1063-1073
-
-
Sauvé, M.1
Ban, K.2
Momen, M.A.3
Zhou, Y.Q.4
Henkelman, R.M.5
Husain, M.6
Drucker, D.J.7
-
3
-
-
77951812608
-
The myocardial infarct size-limiting effect of sitagliptin is pka-dependent, whereas the protective effect of pioglitazone is partially dependent on pka
-
Ye Y, Keyes KT, Zhang C, Perez-Polo JR, Lin Y, Birnbaum Y. The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA. Am J Physiol Heart Circ Physiol. 2010;298:H1454-H1465.
-
(2010)
Am J Physiol Heart Circ Physiol
, vol.298
-
-
Ye, Y.1
Keyes, K.T.2
Zhang, C.3
Perez-Polo, J.R.4
Lin, Y.5
Birnbaum, Y.6
-
4
-
-
79959966874
-
Pre-treatment with a dpp-4 inhibitor is infarct sparing in hearts from obese, pre-diabetic rats
-
Huisamen B, Genis A, Marais E, Lochner A. Pre-treatment with a DPP-4 inhibitor is infarct sparing in hearts from obese, pre-diabetic rats. Cardiovasc Drugs Ther. 2011;25:13-20.
-
(2011)
Cardiovasc Drugs Ther
, vol.25
, pp. 13-20
-
-
Huisamen, B.1
Genis, A.2
Marais, E.3
Lochner, A.4
-
5
-
-
84879120827
-
Cardioprotective effect of dipeptidyl peptidase-4 inhibitor during ischemia-reperfusion injury
-
Chinda K, Palee S, Surinkaew S, Phornphutkul M, Chattipakorn S, Chattipakorn N. Cardioprotective effect of dipeptidyl peptidase-4 inhibitor during ischemia-reperfusion injury. Int J Cardiol. 2013;167:451-457.
-
(2013)
Int J Cardiol
, vol.167
, pp. 451-457
-
-
Chinda, K.1
Palee, S.2
Surinkaew, S.3
Phornphutkul, M.4
Chattipakorn, S.5
Chattipakorn, N.6
-
6
-
-
84872424922
-
An emerging role of dipeptidyl peptidase 4 (dpp4) beyond glucose control: Potential implications in cardiovascular disease
-
Zhong J, Rao X, Rajagopalan S. An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease. Atherosclerosis. 2013;226:305-314.
-
(2013)
Atherosclerosis
, vol.226
, pp. 305-314
-
-
Zhong, J.1
Rao, X.2
Rajagopalan, S.3
-
7
-
-
43249089631
-
Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways
-
Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation. 2008;117:2340-2350.
-
(2008)
Circulation
, vol.117
, pp. 2340-2350
-
-
Ban, K.1
Noyan-Ashraf, M.H.2
Hoefer, J.3
Bolz, S.S.4
Drucker, D.J.5
Husain, M.6
-
8
-
-
77951934948
-
Dpp-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease
-
Read PA, Khan FZ, Heck PM, Hoole SP, Dutka DP. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circ Cardiovasc Imaging. 2010;3:195-201.
-
(2010)
Circ Cardiovasc Imaging
, vol.3
, pp. 195-201
-
-
Read, P.A.1
Khan, F.Z.2
Heck, P.M.3
Hoole, S.P.4
Dutka, D.P.5
-
9
-
-
0142219954
-
Strain, and strain rate echocardiography for the assessment of left and right systolic ventricular function
-
Pellerin D, Sharma R, Elliott P, Veyrat C. Tissue Doppler, strain, and strain rate echocardiography for the assessment of left and right systolic ventricular function. Heart. 2003;89(Suppl 3):iii9-iii17.
-
(2003)
Heart
, vol.89
, Issue.SUPPL. 3
-
-
Pellerin, D.1
Sharma, R.2
Elliott, P.3
Veyrat, C.4
Doppler, T.5
-
10
-
-
0041474935
-
Myocardial doppler in stress echocardiography (mydise) study investigators. Non-invasive diagnosis of coronary artery disease by quantitative stress echocardiography: Optimal diagnostic models using off-line tissue doppler in the mydise study
-
Madler CF, Payne N, Wilkenshoff U, Cohen A, Derumeaux GA, Piérard LA, Engvall J, Brodin LA, Sutherland GR, Fraser AG; Myocardial Doppler in Stress Echocardiography (MYDISE) Study Investigators. Non-invasive diagnosis of coronary artery disease by quantitative stress echocardiography: optimal diagnostic models using off-line tissue Doppler in the MYDISE study. Eur Heart J. 2003;24:1584-1594.
-
(2003)
Eur Heart J
, vol.24
, pp. 1584-1594
-
-
Madler, C.F.1
Payne, N.2
Wilkenshoff, U.3
Cohen, A.4
Derumeaux, G.A.5
Piérard, L.A.6
Engvall, J.7
Brodin, L.A.8
Sutherland, G.R.9
Fraser, A.G.10
-
11
-
-
0038523963
-
Strain-rate imaging during dobutamine stress echocardiography provides objective evidence of inducible ischemia
-
Voigt JU, Exner B, Schmiedehausen K, Huchzermeyer C, Reulbach U, Nixdorff U, Platsch G, Kuwert T, Daniel WG, Flachskampf FA. Strain-rate imaging during dobutamine stress echocardiography provides objective evidence of inducible ischemia. Circulation. 2003;107:2120-2126.
-
(2003)
Circulation
, vol.107
, pp. 2120-2126
-
-
Voigt, J.U.1
Exner, B.2
Schmiedehausen, K.3
Huchzermeyer, C.4
Reulbach, U.5
Nixdorff, U.6
Platsch, G.7
Kuwert, T.8
Daniel, W.G.9
Flachskampf, F.A.10
-
12
-
-
4444286107
-
Comparison of deformation imaging and velocity imaging for detecting regional inducible ischaemia during dobutamine stress echocardiography
-
Voigt JU, Nixdorff U, Bogdan R, Exner B, Schmiedehausen K, Platsch G, Kuwert T, Daniel WG, Flachskampf FA. Comparison of deformation imaging and velocity imaging for detecting regional inducible ischaemia during dobutamine stress echocardiography. Eur Heart J. 2004;25:1517-1525.
-
(2004)
Eur Heart J
, vol.25
, pp. 1517-1525
-
-
Voigt, J.U.1
Nixdorff, U.2
Bogdan, R.3
Exner, B.4
Schmiedehausen, K.5
Platsch, G.6
Kuwert, T.7
Daniel, W.G.8
Flachskampf, F.A.9
-
13
-
-
33846083971
-
Primary prevention of cardiovascular diseases in people with diabetes mellitus: A scientific statement from the american heart association and the
-
Association A D.American Diabetes Association
-
Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, Fonseca V, Gerstein HC, Grundy S, Nesto RW, Pignone MP, Plutzky J, Porte D, Redberg R, Stitzel KF, Stone NJ; American Heart Association; American Diabetes Association. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation. 2007;115:114-126.
-
(2007)
Circulation
, vol.115
, pp. 114-126
-
-
Buse, J.B.1
Ginsberg, H.N.2
Bakris, G.L.3
Clark, N.G.4
Costa, F.5
Eckel, R.6
Fonseca, V.7
Gerstein, H.C.8
Grundy, S.9
Nesto, R.W.10
Pignone, M.P.11
Plutzky, J.12
Porte, D.13
Redberg, R.14
Stitzel, K.F.15
Stone, N.J.16
-
14
-
-
67149142042
-
Bari 2d study group. A randomized trial of therapies for type 2 diabetes and coronary artery disease
-
Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, MacGregor JM, Orchard TJ, Chaitman BR, Genuth SM, Goldberg SH, Hlatky MA, Jones TL, Molitch ME, Nesto RW, Sako EY, Sobel BE; BARI 2D Study Group. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360:2503-2515.
-
(2009)
N Engl J Med
, vol.360
, pp. 2503-2515
-
-
Frye, R.L.1
August, P.2
Brooks, M.M.3
Hardison, R.M.4
Kelsey, S.F.5
MacGregor, J.M.6
Orchard, T.J.7
Chaitman, B.R.8
Genuth, S.M.9
Goldberg, S.H.10
Hlatky, M.A.11
Jones, T.L.12
Molitch, M.E.13
Nesto, R.W.14
Sako, E.Y.15
Sobel, B.E.16
-
15
-
-
33644682164
-
Initial experience with glp-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure
-
Thrainsdottir I, Malmberg K, Olsson A, Gutniak M, Rydén L. Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure. Diab Vasc Dis Res. 2004;1:40-43.
-
(2004)
Diab Vasc Dis Res
, vol.1
, pp. 40-43
-
-
Thrainsdottir, I.1
Malmberg, K.2
Olsson, A.3
Gutniak, M.4
Rydén, L.5
-
16
-
-
33845293219
-
Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure
-
Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail. 2006;12:694-699.
-
(2006)
J Card Fail
, vol.12
, pp. 694-699
-
-
Sokos, G.G.1
Nikolaidis, L.A.2
Mankad, S.3
Elahi, D.4
Shannon, R.P.5
-
17
-
-
1442311383
-
Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion
-
Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, Shannon RP. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation. 2004;109:962-965.
-
(2004)
Circulation
, vol.109
, pp. 962-965
-
-
Nikolaidis, L.A.1
Mankad, S.2
Sokos, G.G.3
Miske, G.4
Shah, A.5
Elahi, D.6
Shannon, R.P.7
-
18
-
-
84863560602
-
Exenatide reduces reperfusion injury in patients with st-segment elevation myocardial infarction
-
Lonborg J, Vejlstrup N, Kelb.k H, Botker HE, Kim WY, Mathiasen AB, Jorgensen E, Helqvist S, Saunamaki K, Clemmensen P, Holmvang L, Thuesen L, Krusell LR, Jensen JS, Kober L, Treiman M, Holst JJ, Engstrom T. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J. 2012;33:1491-1499.
-
(2012)
Eur Heart J
, vol.33
, pp. 1491-1499
-
-
Lonborg, J.1
Vejlstrup, N.2
Kelbk, H.3
Botker, H.E.4
Kim, W.Y.5
Mathiasen, A.B.6
Jorgensen, E.7
Helqvist, S.8
Saunamaki, K.9
Clemmensen, P.10
Holmvang, L.11
Thuesen, L.12
Krusell, L.R.13
Jensen, J.S.14
Kober, L.15
Treiman, M.16
Holst, J.J.17
Engstrom, T.18
-
19
-
-
34547930879
-
Effect of glucagon-like peptide-1 (glp-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting
-
Sokos GG, Bolukoglu H, German J, Hentosz T, Magovern GJ Jr., Maher TD, Dean DA, Bailey SH, Marrone G, Benckart DH, Elahi D, Shannon RP. Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am J Cardiol. 2007;100:824-829.
-
(2007)
Am J Cardiol
, vol.100
, pp. 824-829
-
-
Sokos, G.G.1
Bolukoglu, H.2
German, J.3
Hentosz, T.4
Magovern Jr., G.J.5
Maher, T.D.6
Dean, D.A.7
Bailey, S.H.8
Marrone, G.9
Benckart, D.H.10
Elahi, D.11
Shannon, R.P.12
-
20
-
-
51749088973
-
Effects of intravenous glucagon-like peptide-1 on glucose control and hemodynamics after coronary artery bypass surgery in patients with type 2 diabetes
-
Mussig K, Oncu A, Lindauer P, Heininger A, Aebert H, Unertl K, Ziemer G, Haring HU, Holst JJ, Gallwitz B. Effects of intravenous glucagon-like peptide-1 on glucose control and hemodynamics after coronary artery bypass surgery in patients with type 2 diabetes. Am J Cardiol. 2008;102:646-647.
-
(2008)
Am J Cardiol
, vol.102
, pp. 646-647
-
-
Mussig, K.1
Oncu, A.2
Lindauer, P.3
Heininger, A.4
Aebert, H.5
Unertl, K.6
Ziemer, G.7
Haring, H.U.8
Holst, J.J.9
Gallwitz, B.10
-
21
-
-
84857111888
-
Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease
-
Read PA, Khan FZ, Dutka DP. Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease. Heart. 2012;98:408-413.
-
(2012)
Heart
, vol.98
, pp. 408-413
-
-
Read, P.A.1
Khan, F.Z.2
Dutka, D.P.3
-
22
-
-
84860390563
-
A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans
-
Read PA, Hoole SP, White PA, Khan FZ, O'Sullivan M, West NE, Dutka DP. A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans. Circ Cardiovasc Interv. 2011;4:266-272.
-
(2011)
Circ Cardiovasc Interv
, vol.4
, pp. 266-272
-
-
Read, P.A.1
Hoole, S.P.2
White, P.A.3
Khan, F.Z.4
O'Sullivan, M.5
West, N.E.6
Dutka, D.P.7
-
23
-
-
80052072913
-
Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: Evidence for improving cardiac metabolic efficiency
-
Bao W, Aravindhan K, Alsaid H, Chendrimada T, Szapacs M, Citerone DR, Harpel MR, Willette RN, Lepore JJ, Jucker BM. Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: evidence for improving cardiac metabolic efficiency. PLoS One. 2011;6:e23570.
-
(2011)
PLoS One
, vol.6
-
-
Bao, W.1
Aravindhan, K.2
Alsaid, H.3
Chendrimada, T.4
Szapacs, M.5
Citerone, D.R.6
Harpel, M.R.7
Willette, R.N.8
Lepore, J.J.9
Jucker, B.M.10
-
24
-
-
0037629509
-
Glucagon-like peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium
-
Kavianipour M, Ehlers MR, Malmberg K, Ronquist G, Ryden L, Wikstrom G, Gutniak M. Glucagon-like peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium. Peptides. 2003;24:569-578.
-
(2003)
Peptides
, vol.24
, pp. 569-578
-
-
Kavianipour, M.1
Ehlers, M.R.2
Malmberg, K.3
Ronquist, G.4
Ryden, L.5
Wikstrom, G.6
Gutniak, M.7
-
25
-
-
0019543906
-
Alterations of carbohydrate and lipid metabolism in the acutely ischemic heart
-
Liedtke AJ. Alterations of carbohydrate and lipid metabolism in the acutely ischemic heart. Prog Cardiovasc Dis. 1981;23:321-336.
-
(1981)
Prog Cardiovasc Dis
, vol.23
, pp. 321-336
-
-
Liedtke, A.J.1
-
26
-
-
84862908699
-
A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein e-deficient mice
-
Matsubara J, Sugiyama S, Sugamura K, Nakamura T, Fujiwara Y, Akiyama E, Kurokawa H, Nozaki T, Ohba K, Konishi M, Maeda H, Izumiya Y, Kaikita K, Sumida H, Jinnouchi H, Matsui K, Kim-Mitsuyama S, Takeya M, Ogawa H. A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. J Am Coll Cardiol. 2012;59:265-276.
-
(2012)
J Am Coll Cardiol
, vol.59
, pp. 265-276
-
-
Matsubara, J.1
Sugiyama, S.2
Sugamura, K.3
Nakamura, T.4
Fujiwara, Y.5
Akiyama, E.6
Kurokawa, H.7
Nozaki, T.8
Ohba, K.9
Konishi, M.10
Maeda, H.11
Izumiya, Y.12
Kaikita, K.13
Sumida, H.14
Jinnouchi, H.15
Matsui, K.16
Kim-Mitsuyama, S.17
Takeya, M.18
Ogawa, H.19
-
27
-
-
0037432293
-
Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization
-
Yamaguchi J, Kusano KF, Masuo O, Kawamoto A, Silver M, Murasawa S, Bosch-Marce M, Masuda H, Losordo DW, Isner JM, Asahara T. Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization. Circulation. 2003;107:1322-1328.
-
(2003)
Circulation
, vol.107
, pp. 1322-1328
-
-
Yamaguchi, J.1
Kusano, K.F.2
Masuo, O.3
Kawamoto, A.4
Silver, M.5
Murasawa, S.6
Bosch-Marce, M.7
Masuda, H.8
Losordo, D.W.9
Isner, J.M.10
Asahara, T.11
-
28
-
-
33750445289
-
Nitric oxide and atherosclerosis: An update
-
Napoli C, de Nigris F, Williams-Ignarro S, Pignalosa O, Sica V, Ignarro LJ. Nitric oxide and atherosclerosis: an update. Nitric Oxide. 2006;15:265-279.
-
(2006)
Nitric Oxide
, vol.15
, pp. 265-279
-
-
Napoli, C.1
De Nigris, F.2
Williams-Ignarro, S.3
Pignalosa, O.4
Sica, V.5
Ignarro, L.J.6
-
29
-
-
77958195997
-
The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: Possible role of stromal-derived factor-1alpha
-
Fadini GP, Boscaro E, Albiero M, Menegazzo L, Frison V, de Kreutzenberg S, Agostini C, Tiengo A, Avogaro A. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha. Diabetes Care. 2010;33:1607-1609.
-
(2010)
Diabetes Care
, vol.33
, pp. 1607-1609
-
-
Fadini, G.P.1
Boscaro, E.2
Albiero, M.3
Menegazzo, L.4
Frison, V.5
De Kreutzenberg, S.6
Agostini, C.7
Tiengo, A.8
Avogaro, A.9
-
30
-
-
84876780409
-
Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes
-
Matsubara J, Sugiyama S, Akiyama E, Iwashita S, Kurokawa H, Ohba K, Maeda H, Fujisue K, Yamamoto E, Kaikita K, Hokimoto S, Jinnouchi H, Ogawa H. Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes. Circ J. 2013;77:1337-1344.
-
(2013)
Circ J
, vol.77
, pp. 1337-1344
-
-
Matsubara, J.1
Sugiyama, S.2
Akiyama, E.3
Iwashita, S.4
Kurokawa, H.5
Ohba, K.6
Maeda, H.7
Fujisue, K.8
Yamamoto, E.9
Kaikita, K.10
Hokimoto, S.11
Jinnouchi, H.12
Ogawa, H.13
|